Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, Bio-Rad Settle on Lawsuit Claiming Patent Infringement of SPR Technology

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GE Healthcare today it has settled with Bio-Rad Laboratories over litigation related to GE Healthcare Life Sciences' technology for studying molecular interactions with surface plasmon resonance.

Financial terms of the settlement were not disclosed. In 2010 GE Healthcare sued Bio-Rad in Germany alleging infringement of SPR-related patents.

GE Healthcare said that it and Bio-Rad have withdrawn their claims and GE Healthcare has granted a license to Bio-Rad to a collection of patents, which relate to certain aspects of GE Healthcare's technology and Biacore instrument for SPR-based quantitative studies of molecular interactions.

The non-exclusive license gives Bio-Rad rights to use GE Healthcare's technologies in Bio-Rad's SPR products.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.